AZ builds case for its COPD triple as it chases GSK’s Trelegy

Breztri has its first approval in hand – in Japan – but isn’t due for regulatory decisions in Europe and the US until next year.

GSK files anaemia drug daprodustat in Japan, its first market

class called vadadustat in late-stage clinical testing that is licensed to Mitsubishi Tanabe Pharma in some Asian markets including Japan. ... Astellas Pharma meanwhile has rights to roxadustat in Japan and Europe and has phase 3 trials on the go in

AbbVie scores FDA approval for arthritis treatment upadacitinib

Could find it difficult to live up to Humira

Leo Pharma to market AstraZeneca’s brodalumab outside Europe

The rights to the psoriasis treatment are owned by Kyowa Kirin in Japan and other Asian countries.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]